Panacea Biotec sets Sept 29 for 42nd AGM; book closure starts Sept 25

scanx
Reviewed by
Anirudha BScanX News Team
Key Highlights
  • Panacea Biotec holds 42nd AGM on September 29, 2026, via video conferencing at 11:30 am
  • Register of members closes from September 25 to September 29, 2026
  • Shareholders vote on re-appointment of directors Ankesh Jain and Harshet Jain
  • Rajinder Singh Manku appointed as independent director for five-year term starting July 1, 2026
  • Cost auditor fee ratified at ₹1,25,000 for FY27
powered bylight_fuzz_icon
50343621

*this image is generated using AI for illustrative purposes only.

Panacea Biotec will hold its 42nd Annual General Meeting on September 29, 2026, at 11:30 am via video conferencing. The register of members will close from September 25 to September 29, 2026.

The meeting agenda includes the adoption of audited standalone and consolidated financial statements for FY26. Shareholders will also vote on the re-appointment of directors Ankesh Jain and Harshet Jain, who retire by rotation.

Board Appointments

A special resolution seeks approval for the appointment of Rajinder Singh Manku as an independent director. His term begins July 1, 2026, for five consecutive years. The Nomination and Remuneration Committee recommended his candidacy based on his experience in project planning and finance.

Director Role Status
Ankesh Jain Whole-time Director Re-appointment
Harshet Jain Whole-time Director Re-appointment
Rajinder Singh Manku Independent Director New Appointment

Cost Auditor Remuneration

The board proposes ratifying the remuneration for cost auditors M/s Jain Sharma & Associates. The fee is set at ₹1,25,000 for the financial year 2026-27. This amount includes out-of-pocket expenses but excludes outstation travel costs and applicable taxes.

Voting and Participation

Remote e-voting opens on September 26, 2026, at 9:00 am and closes on September 28, 2026, at 5:00 pm. The cut-off date for voting eligibility is September 22, 2026. Members can attend the meeting through the NSDL e-voting system. Physical copies of the annual report are available only upon request.

Historical Stock Returns for Panacea Biotec

1 Day5 Days1 Month6 Months1 Year5 Years
-0.75%-4.32%-9.78%+18.10%-7.13%0.0%

How might the appointment of Rajinder Singh Manku, with his finance and project planning background, influence Panacea Biotec's future capital allocation or expansion strategies?

What specific growth targets or strategic priorities are expected to be outlined in the FY26 audited financial statements that shareholders will adopt?

Could the re-appointment of directors Ankesh Jain and Harshet Jain signal continuity in current management strategies, or are investors anticipating shifts in operational focus?

Panacea Biotec AGM set for September 29 via video conference

scanx
Reviewed by
Anirudha BScanX News Team
Key Highlights

Panacea Biotec Limited will hold its 42nd AGM on September 29, 2026, via VC/OAVM. The meeting aims to adopt FY25-26 financials. Shareholders must register emails with RTA Skyline Financial Services to access notices and e-voting credentials. Physical shareholders are urged to update details to participate effectively.

powered bylight_fuzz_icon
48598661

*this image is generated using AI for illustrative purposes only.

Panacea Biotec Limited ( Panacea Biotec ) has scheduled its 42nd Annual General Meeting (AGM) for Tuesday, September 29, 2026, at 11:30 am. The meeting will be held exclusively through Video Conferencing or Other Audio-Visual Means (VC/OAVM), adhering to the provisions of the Companies Act, 2013, and circulars issued by the Ministry of Corporate Affairs and the Securities and Exchange Board of India.

The deemed venue for the AGM is the company’s registered office located on the Ambala-Chandigarh Highway in Lalru, Punjab. Shareholders will have the opportunity to transact the business items outlined in the AGM notice, which includes the adoption of audited financial statements for the financial year 2025-26.

E-voting and Participation Details

Members holding shares in demat or physical form can cast their votes electronically through remote e-voting or during the AGM via the VC/OAVM facility. The company has engaged Skyline Financial Services Pvt. Ltd. as its Registrar and Share Transfer Agent (RTA) to facilitate these processes.

Key logistical details for shareholders include:

  • Notice Dispatch: The AGM notice and Annual Report for FY25-26 will be sent electronically only to members who have registered their email addresses with the company, RTA, or Depository Participants (DPs).
  • Physical Shareholders: Members holding shares in physical form without registered emails are requested to update their details at the RTA’s portal to receive the notice and voting credentials.
  • Demat Shareholders: Those holding shares in demat form should contact their respective DPs to ensure their contact information is up to date.

The remote e-voting window and specific login instructions will be detailed in the formal notice of the AGM. Members who vote remotely prior to the meeting may attend the virtual session but cannot vote again. Conversely, those who do not vote remotely can cast their votes during the live AGM session.

Regulatory Compliance

This announcement aligns with Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The public notice regarding the AGM was published in Business Standard (all editions) and Desh Sewak (Punjabi) on August 18, 2026, ensuring broad dissemination among stakeholders.

Historical Stock Returns for Panacea Biotec

1 Day5 Days1 Month6 Months1 Year5 Years
-0.75%-4.32%-9.78%+18.10%-7.13%0.0%

How might the adoption of the FY25-26 audited financial statements influence Panacea Biotec's dividend policy or share buyback plans?

What strategic initiatives or capital expenditure projects are likely to be prioritized in the upcoming fiscal year based on the AGM agenda?

Could the exclusive use of VC/OAVM for the AGM signal a broader shift in corporate governance practices for Indian biotech firms?

More News on Panacea Biotec

1 Year Returns:-7.13%